CTRI/2012/11/003151Not yet recruitingPhase 4
Prospective Observational Study to Assess the Safety and Efficacy of Once-Daily Tamcontin® Tablet (Continus® Controlled release tablet of Tamsulosin Hydrochloride, 0.4 mg) in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia (BPH) in the Routine Clinical Practice
ModiMundiPharma Pvt Ltd0 sites100 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 4
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Pms
Eligibility Criteria
Inclusion Criteria
- •Newly diagnosed, treatment naive BPH patients eligible to receive Tamsulosin hydrochloride, 0.4 mg in the routine clinical practice
Exclusion Criteria
- •Not Applicable
Investigators
Similar Trials
Recruiting
Not Applicable
Prospective observational study for the safety and efficacy of chemotherapy in gastric cancergastric cancerJPRN-UMIN000044817Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences150
Recruiting
Phase 4
An Observational Study to evaluate the safety and efficacy of Cetuximab in combination with platinum-based chemotherapy, in the first-line therapy of recurrent/ metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)CTRI/2010/091/000170Merck Specialities Pvt Ltd5th Floor Shiv Sagar Estate, Dr. Aniie Besant Road, WorliMumbai 400018100
Recruiting
Phase 3
A prospective observational study on the safety and efficacy of cryobiopsy using an ultrathin cryoprobe and a therapeutic bronchoscope to evaluate endobronchial lesions in patients under conscious sedatioEndotracheal or endobronchial lesionsJPRN-UMIN000050606ational Hospital Organization Nagoya Medical Center30
Recruiting
Not Applicable
An observational study to evaluate the safety and efficacy of MegaDerm Soft in patients who underwent breast reconstruction using the MegaDerm soft.KCT0007432Soon Chun Hyang University Hospital Bucheon60
Recruiting
Phase 4
An observational study to evaluate the safety and efficacy of FOLFIRI / FOLFOX plus Cetuximab as first-line therapy inpatients with KRAS wild-type metastatic Colorectal cancerCTRI/2010/091/000161Merck Specialities Pvt Limited5th Floor , Shivsagar EstateDr. Annie Besant RoadMumbai 400018100